FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO. CO14CIP DIV1

SERIAL NO. Not Yet Asstr

APPLICANT

Michael J. Yellin et al.

GROUP-

FILING DATE Concurrently Herewith

Not Yet Assign

1644 04/34300(LIS PATENT DOCUMENTS

		Į	J.S. PATENT DOCUMEN	rs ''		<u> </u>
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Mu	5,474,771	12/12/95	Lederman et al.	424	85.8	Nov. 15, 1991
1	5,540,926	7/30/96	Aruffo et al.	424	153.1	Sept. 4, 1992
	5,674,492	10/7/97	Armitage et al.	424	144.1	Dec. 23, 1993 Dec. 21, 1994
	5,677,165	10/14/97	de Boer et al.	435	240.27	July 9, 1992 May 28, 1993
	5,683,693	11/4/97	Noelle et al.	424	144.1	April 25, 1994
	5,747,037	5/5/98	Noelle et al.	424	154.1	Sept. 2, 1993 April 25, 1994 June 7, 1995
- NS	5,833,987	11/10/98	Noelle et al.	424	154.1	June 7, 1995
**						<u></u>
						,
· · · · · · · · · · · · · · · · · · ·						
<u>.</u>						
						

EXAMINER

PHLLIP GAMBER 12/14/00

NO

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. PATENT AND TRADEMARK OFFICE CO14CIP DIV1 Not Yet Assigned 09 (343001 **APPLICANT** INFORMATION DISCLOSURE Michael J. Yellin et al. 4644 STATEMENT BY APPLICANT FILING DATE **GROUP** Concurrently Herewith Not Yet Assigned FOREIGN PATENT DOCUMENTS TRANSLATION **EXAMINER DOCUMENT NUMBER** DATE COUNTRY **CLASS SUBCLASS INITIAL** YES M WO 93/08207 4/29/93 **PCT** C07H 21/00 **PCT** WO 93/09812 5/27/93 39/395 A61K WO 94/04570 3/3/94 PCT C07K 15/06 WO 95/06481 3/9/95 PCT A61K 39/395 WO 95/06666 3/9/95 PCT C07K 16/28 WO 95/09653 4/13/95 PCT **A61K** 39/395 WO 96/23071 8/1/96 PCT C12N 15/13 WO 96/28568 9/19/96 PCT **C12P** 21/02 WO 96/40246 12/19/96 **PCT** A61K 39/395 WO 97/17446 5/15/97 PCT **C12N** 15/13

EXAMINER

PHUPGAMBER 12/14/00

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CO14CIP DIV1	SERIAL NO. Not Yet Assigned	
	IFORMATION DISCLOSURE	APPLICANT Michael J. Yellin et al.	09/34300 (1644	
STATEMENT BY APPLICANT	TATEMENT BY APPLICANT	FILING DATE Concurrently Herewith	GROUP Not Yet Assigned	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) **EXAMINER** INITIAL Alderson, M.R. et al. "CD40 Expression By Human Monocytes: Regulation By Cytokines And M Activation Of Monocytes By The Ligand For CD40", J. Exp. Med. 178:669-674 (1993). Bajorath J. et al. "Identification of Residues on CD40 and Its Ligand Which Are Critical for the Receptor-Ligand Interaction", Biochemistry 34:1833-1844 (1995). Banchereau J. et al. "The CD40 Antigen and its Ligand", Annual Rev. Immunol. 12:881-922 (1994). Biancone, L. et al. "Inhibition of the CD40-CD40Ligand Pathway Prevents Murine Membranous Glomerulonephritis", Kidney Intl. 48:458-468 (1995). Buhlmann, J.E. et al. "Therapeutic Potential For Blockade of the CD40 Ligand, gp39", J. Clin. Immunol. 16:83-89 (1996). Carbone, A. et al. "Expression of Functional CD40 Antigen on Reed-Sternberg Cells and Hodgkin's Disease Cell Lines", Blood 85(3):780-789 (1995). Clark, E.A. et al. "Activation of Human B Cells Mediated Through Two Distinct Cell Surface Differentiation Antigens, Bp35 and Bp5O", Proc. Natl. Acad. Sci., USA 83:4494-4498 (1986). Cleary, A. M. et al. "Opposing Roles of CD95 (Fas/APO-1) and CD40 in the Death and Rescue of Human Low Density Tonsillar B Cells", J. Immunol. 155:3329-3337 (1995). Durie, F.H. et al. "The Role of CD40 and its Ligand (gp39) in Peripheral and Central Tolerance and its Contribution to Autoimmune Disease", Res. Immunol. 145:200-205 (1994). Durie, F.H. et al. "The Role of CD40 in the Regulation of Humoral and Cell-Mediated Immunity", Immunol. Today 15:406-411 (1994). Durie, F.H. et al. "Prevention of Collagen-Induced Arthritis With An Antibody to gp39, the Ligand for CD40", Science 261:1328-1330 (1993). Fanslow W. C. et al. "Soluble Forms of CD40 Inhibit Biologic Responses of Human B Cells", J. Immunol. 149:655-660 (1992). Freudenthal, P.S. et al. "The Distinct Surface of Human Blood Dendritic Cells, As Observed After An Improved Isolation Method", Proc. Natl. Acad. Sci., USA 87:7698-7702 (1990). Galy, A.H.M. et al. "CD40 is Functionally Expressed on Human Thymic Epithelial Cells", J. Immunol. 149:775-782 (1992). Gray, D. et al "Memory B Cell Development But Not Germinal Center Formation is Impaired by In Vivo Blockade of CD-40-CD40 Ligand Interaction", J. Exp. Med. 180:141-154 (1994). Hasbold, J. et al. "Properties of Mouse CD40: Cellular Distribution of CD40 and B Cell Activation by Monoclonal Anti-Mouse CD40 Antibodies", Eur. J. Of Immunol. 24:1835-1842 (1994). Hollenbaugh, D. et al. "Expression of Functional CD40 by Vascular Endothelial Cells", J. Exp. Med.

EXAMINER

PHLLIPGAMOER 18/14/00

182:33-40 (1995).

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO.	SERIAL NO.		
CO14CIP DIV1	Not Yet Assigned		
APPLICANT	09/343001		
Michael J. Yellin et al.	644		
FILING DATE Concurrently Herewith	GROUP Not Yet Assigned		

OTHER DOCUMENTS (Including Author Title Date Pertinent Pages, Etc.)

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EXAMINER INITIAL			
Me	Karmann, K. et al. "CD40 on Human Endothelial Cells: Inducibility by Cytokines and Functional Regulation of Adhesion Molecule Expression", <i>Proc. Natl. Acad. Sci., USA</i> 92:4342-4346 (1995).		
	Karpusas, M. et al. "2Å Crystal Structure of an Extracellular Fragment of Human CD40 Ligand", Structure 3(10): 1031-1039 (1995).		
	Kuntz, I.D. "Structure-Based Strategies for Drug Design and Discovery", <i>Science</i> 257:1078-1082 (1992).		
	Kuwana, M. et al. "T and B Cell Collaboration is Essential for the Autoantibody Response to DNA Topoisomerase 1 in Systemic Sclerosis", <i>J. Immunol.</i> 155:2703-2714 (1995).		
	Laman, J.D. et al. "The Role of GP39 (CD40 Ligand) in EAE and MS", J. Neuroimmunology 54:175 (1994).		
	Larsen, C.P. et al. "CD40-gp39 Interactions Play A Critical Role During Allograft Rejection", Transplantation 61:4-9 (1996).		
	Law, C-L. et al. "Analysis of Expression and Function of CD40 on Normal and Leukemic Human B Cell Precursors", <i>Leukemia</i> 4(11):732-738 (1990).		
	Lederman, S. et al. "The Understanding of Contact-Dependent T-Cell Helper Function in Molecular, Cellular and Physiological Detail", Res. Immunol. 145:215-222 (1994).		
	Mohan, C. et al. "Interaction Between CD40 and Its Ligand gp39 in the Development of Murine Lupus Nephritis", <i>J. Immunol.</i> 154:1470-1480 (1995).		
	Merck Manual of Diagnosis And Therapy, 16th Ed. "Idiopathic Infiltrative Diseases Of The Lungs", Merck Research Laboratories, Rahway, NJ 718-720 (1992).		
	O'Grady, J.T. et al. "CD40 Expression in Hodgkin's Disease", Am. J. Of Pathology 144:(I):2126 (1994).		
	Paulie, S. et al. "A p5O Surface Antigen Restricted to Human Urinary Bladder Carcinomas and B Lymphocytes", Cancer Immunol. Immunother. 20:23-28 (1985).		
	Potocnik, A.J. et al. "Expression of Activation Antigens on T Cells in Rheumatoid Arthritis Patients", Scand. J. Immunol. 31:213-224 (1990).		
	Stüber, E. et al. "Blocking The CD-40L-CD-40 Interaction In Vivo Specifically Prevents the Priming of T Helper 1 Cells Through The Inhibition of Interleukin 12 Secretion", <i>J. Exp. Med.</i> 183: 693-698 (1996).		
	Uckun, F.M. et al. "Temporal Association of CD40 Antigen Expression With Discrete Stages of Human B-Cell Ontogeny and the Efficacy of Anti-CD40 Immunotoxins Against Clonogenic B-Lineage Acute Lymphoblastic Leukemia As Well As B-Lineage Non-Hodgkin's Lymphoma Cells", <i>Blood</i> 76(12):2449-2456 (1990).		
M	Urashima, M. et al. "CD40 Ligand Triggered Interleukin-6 Secretion In Multiple Myeloma", <i>Blood</i> 85:1903-1912 (1995).		

EXAMINER

PHUPGAMEST

12/14/00

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO. CO14CIP DIV1	SERIAL NO. Not Yet Assigned
APPLICANT Michael J. Yellin et al.	09(34300)
FILING DATE Concurrently Herewith	GROUP Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
EXAMINER INITIAL				
W	Valent, P. et al. "Further Characterization Of Surface Membrane Structures Expressed On Human Basophils And Mast Cells", <i>Int. Arch. Allergy Appl. Immunol.</i> 91:198-203 (1990).			
	Westendorf, J.J. et al. "Molecular And Biological Role Of CD40 In Multiple Myeloma", Curr. Top. Microbiol. Immunol. 194:63-72 (1995).			
	Westendorf, J.J. et al. "CD40 Expressions In Malignant Plasma Cells", J. Of Immunol. 152:117-128 (1994).			
	Yellin, M.J. et al. "FASEB J. (March 10, 1995) 9(4):A774, Abstract No. 4483 - Oral presentation at FASEB Meeting in Atlanta, Georgia" (1995).			
	Yellin, M.J. et al. "Human Fibroblasts and Endothelial Cells Express CD40 and are Activated by CD40L+ Cells," Poster session at 9th International Congress of Immunology meeting in San Francisco, California (Abstract available July 23, 1995).			
	Yellin, M.J. et al. "Ligation Of CD40 On Fibroblasts Induces CD54 (ICAM-1) and CD106 (VCAM-1) Upregulation And IL-6 Production And Proliferation," <i>J. Leukocyte Biology</i> 58:209-216 (1995).			
	Yellin, M.J. et al. "Functional Interactions Of T Cells With Endothelial Cells: The Role Of CD40L-CD40-Mediated Signals," <i>J. Exp. Med.</i> 182:1857-1864 (1995).			
	Yellin M. J. et al. "In situ Characterization of CD40L and CD40 Expression in Glomerulonephritis (GN)", Abstract May 1, 1996: ASBMB/ASIP/AAI Joint Meeting.			
	Yellin M. J. et al. "Function of CD40 Molecules Expressed on Cultured Synovial Membrane Fibroblasts", FASEB J. 9:A774 - Abstract No. 4483 (1995).			
M	Young, L.S. et al. "Identification Of A Human Epithelial Cell Surface Protein Sharing An Epitope With The C3d/Epstein-Barr Virus Receptor Molecule Of B Lymphocytes," <i>Int. J. Cancer</i> 43:786-794 (1989).			
- Affin Co. Co.				

EXAMINER

PHUNGAMOR 12/14/00